Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.63 |
| ▸ | KDR | P35968 | 5/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.61 |
| ▸ | ABL1 | P00519 | 3/20 | 0.61 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.61 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.61 |
| ▸ | PLK4 | O00444 | 2/20 | 0.61 |
| ▸ | AURKA | O14965 | 2/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.61 |
| ▸ | LCK | P06239 | 2/20 | 0.61 |
| ▸ | FYN | P06241 | 2/20 | 0.61 |
| ▸ | LYN | P07948 | 2/20 | 0.61 |
| ▸ | SRC | P12931 | 2/20 | 0.61 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.61 |
| ▸ | AXL | P30530 | 2/20 | 0.61 |
| ▸ | FRK | P42685 | 2/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.61 |
| ▸ | BLK | P51451 | 2/20 | 0.61 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6426658 | 0.97 | KDR (0.66) | RETKDRMAPK14ABL1EPHA2 | |
| SCHEMBL6387944 | 0.94 | RET (0.63) | RETKDRMAPK14ABL1EPHA2 | |
| SCHEMBL6474265 | 0.92 | RAF1 (0.66) | RETKDRMAPK14ABL1EPHA2 | |
| SCHEMBL6384112 | 0.88 | RET (0.59) | RETKDRMAPK14ABL1EPHA2 | |
| SCHEMBL6382324 | 0.87 | RAF1 (0.65) | RETKDRMAPK14ABL1EPHA2 | |
| SCHEMBL6480098 | 0.87 | RAF1 (0.60) | RETKDRMAPK14ABL1EPHA2 | |
| SCHEMBL6385513 | 0.87 | RAF1 (0.60) | RETKDRMAPK14ABL1EPHA2 | |
| SCHEMBL6384913 | 0.87 | RAF1 (0.66) | RETKDRMAPK14ABL1EPHA2 | |
| SCHEMBL6388680 | 0.86 | BRAF (0.55) | RETKDRMAPK14ABL1EPHA2 | |
| SCHEMBL6385804 | 0.85 | RET (0.62) | RETKDRMAPK14ABL1EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | claimed |
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | BAYER HEALTHCARE LLC | 2005-02-17 | — | — | US | claimed |
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076488-B2 | Antiproliferative agents; angiogenesis inhibitors; anticancer agents | BAYER HEALTHCARE LLC (US) | 2011-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038031-A1 | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders | CCNC, UACA, SLC14A1 | RET 682/4885KDR 502/4885MAPK14 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.